What Aptuit LLC does

Aptuit LLC is a United States-based contract research organization (CRO) headquartered in Greenwich and founded in 2004, operating with a workforce in the 1,001-5,000 employee band. The firm is positioned as a full-service drug discovery and preclinical development partner for pharmaceutical and biotechnology companies, addressing core client pain points including prolonged discovery timelines, escalating R&D costs, and the integration challenges of personalized medicine and laboratory automation.

The company's service portfolio spans the early R&D value chain. Through organic build and a series of acquisitions completed between 2005 and 2016 - Almedica (2005-07-19), SSCI for solid-state chemistry capabilities (2006-10-01), Exquiron Biotech for biology services (2016-04-21), and Kuecept (2016-05-10) - Aptuit accumulated specialized capabilities in formulation, solid-state chemistry, and discovery biology. A partnership record indicates engagement with Synsight (acquired by Iktos) to integrate the MT Bench system into the drug discovery workflow, dated 2024-07, suggesting the firm is exploring AI-assisted in silico tooling, although no first-party AI platform is documented in the available sources.

The business model follows standard CRO mechanics: fee-for-service and likely FTE-based engagements with pharmaceutical and biotech customers requiring outsourced drug discovery and preclinical development support. Pricing models and per-program contract structures are not publicly disclosed. Customer targeting is horizontal across pharma and biotech rather than vertical-specialized, with the global drug discovery market context (projected at $250.51B by 2030 at a 15.1% CAGR) defining the addressable opportunity. Revenue figures, ownership structure, and detailed financial metrics are not disclosed in the available sources.

Name

Aptuit LLC

Legal name

Evotec

Website

https://aptuit.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aptuit LLC is a U.S.-based CRO providing drug discovery and preclinical development services, including formulation and solid-state chemistry, to pharmaceutical and biotechnology companies. Founded in 2004 and headquartered in Greenwich, it serves horizontal pharma/biotech R&D outsourcing demand.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract research services
• Drug discovery
• Preclinical development
• Pharmaceutical research
• Medicinal chemistry

Headquarters

HQ city

Greenwich

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D

Marketing channels1 record

Core offering

Aptuit LLC is a contract research organization that provides outsourced drug discovery and preclinical development services to pharmaceutical and biotechnology companies. Its offerings span medicinal chemistry, in vitro and in vivo biology, DMPK/ADME, toxicology, formulation, and analytical chemistry to support lead identification, lead optimization, and IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Brands

• Just - Evotec Biologics: Biologics Manufacturing - has revolutionized the design, development, and manufacturing of biologics, making high-quality therapies more accessible and affordable
• Cyprotex

Products and services

• Drug Discovery Services Outsourced drug discovery support for pharmaceutical and biotechnology sponsors, spanning medicinal chemistry, biology, and lead identification/optimization work.
• Preclinical Development Services Preclinical development support covering DMPK/ADME, toxicology, formulation sciences, and analytical chemistry to advance candidates to IND-enabling stages.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• SynsightcoreTechnology or Integration · 1 July 2024Iktos, a French pharmaceutical and biotech firm, completed the acquisition of Synsight, a biotechnology company, to integrate Synsight's MT Bench system into its drug discovery platform. Financial terms were not disclosed.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Evotec SE: Evotec is a global drug discovery and preclinical CRO offering integrated small molecule and biologics services, the closest functional peer to Aptuit's contract research operations; it is also referenced in the company data as an apparent acquirer of Aptuit-like assets.
• Cyprotex (Evotec subsidiary): Cyprotex is a specialist ADME-Tox and DMPK services provider within the Evotec network, an emerging-niche peer offering preclinical capabilities directly comparable to parts of Aptuit's discovery/preclinical CRO portfolio.

Broad incumbents

• Charles River Laboratories: Charles River Laboratories is a broad incumbent CRO/CDMO offering discovery, preclinical, and manufacturing services across small molecules and biologics, overlapping with Aptuit's discovery-to-preclinical scope as part of a much larger portfolio.
• WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO providing drug discovery, preclinical, and clinical development services with extensive scale in chemistry and biology, a direct competitor for outsourced drug discovery programs served by Aptuit.
• IQVIA: IQVIA is a major CRO serving biopharma across clinical development and related R&D services; while more weighted to clinical, its R&D Solutions offerings compete with Aptuit's discovery and preclinical positioning.
• ICON plc: ICON plc is a global CRO with extensive capabilities across clinical and lab services following the PRA Health Sciences merger, competing for outsourced R&D budgets relevant to Aptuit's biopharma clients.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development (Covance) provides preclinical, clinical, and central lab services to biopharma, offering a comparable early-phase discovery and development adjacency relevant to Aptuit customers.
• Syneos Health: Syneos Health is a clinical-focused biopharma services provider with preclinical-adjacent offerings, overlapping with Aptuit's customer base of pharmaceutical and biotech sponsors.
• Medpace: Medpace is a mid-to-large CRO focused on clinical development for biopharma, sharing the same sponsor customers as Aptuit and competing for share of their outsourced R&D wallet.

Emerging players

• BioDuro: BioDuro is a global CRO/CDMO offering drug discovery, development, and manufacturing services, with growing capacity in medicinal chemistry and biology that directly overlaps with Aptuit's integrated CRO scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aptuit
• Xx.com/aptuit

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptuit LLC